Acta Anatomica Sinica ›› 2017, Vol. 48 ›› Issue (3): 303-309.doi: 10.16098/j.issn.0529-1356.2017.03.009

• Cancer Biology • Previous Articles     Next Articles

Expression and significance of apoptosis inhibitor 5 in ovarian cancer

WANG Juan1 HUA Xiao-tang 2*   

  1. 1. Department of Gynecology and Obstetrics, Nantong Rudong County People’s Hospital, Jiangsu Nantong 226400, China;

    2. Department of Gynecology, Affiliated Branch Hospital of Nantong University,Jiangsu Nantong 226001,  China

  • Received:2016-10-12 Revised:2017-02-09 Online:2017-06-06 Published:2017-09-19
  • Contact: HUA Xiao-tang E-mail:ntfyhxt@163.com

Abstract:

Objective The study is designed to investigate the expression of apoptosis inhibitor 5(API5)in ovarian cancer(OC), and to analysis its association with clinical pathologic variables. Methods API5 expression was evaluated by Western blotting in two normal ovarian tissues and six different fresh OC tissues. Immunohistochemistry analysis was performed on formalin-fixed paraffinembedded sections of 10 normal tissues and 119 cases of OCs (including 61 serous papillary adenocarcinoma, 10 endometrioid adenocarcinoma, 10 clear cell carcinoma, 5 mucinous papillary carcinoma, and 33 specimens were classified as undifferentiated carcinoma). SiRNA transfection and flow cytometry showed the impact of API5 and cisplatin on ovarian cancer cells. Results The expression of API5 was higher in the cancer samples compared with that in the normal ovary tissues. API5 was significantly associated with clinical pathologic variables(P<0.05). Kaplan-Meier curve showed that high expression of API5 was related to poor prognosis of OC patients than that low expression. Decreasing the expression of API5 enhanced EOC cell line’s sensibility to cisplatin by flow cytometry. Conclusion Our findings suggest that API5 is involved in the progression of OC and has a potential clinical application value in the assessment of prognosis, which may be a target of therapy in OC.

Key words: Ovarian cancer, Apoptosis inhibitor 5, Cisplatin, Immunohistochemistry, Human